Intraocular pressure (IOP) is still the main treatment target for glaucoma. Outflow resistance mainly exists at the trabecular meshwork (TM) outflow pathway, which is responsible for IOP regulation. Changes of TM cellularity and TM extracellular matrix turnover may play important roles in IOP regulation. In this article, we review basic anatomy and physiology of the outflow pathway and TM stem cell characteristics regarding the location, isolation, identification and function. TM stem cells are localized at the insert region of the TM and are label-retaining in vivo. They can be isolated by side-population cell sorting, cloning culture, or sphere culture. TM stem cells are multipotent with the ability to home to the TM region and differentiate into TM cells in vivo. Other stem cell types, such as adipose-derived stem cells, mesenchymal stem cells and induced pluripotent stem cells have been discovered for TM cell differentiation and TM regeneration. We also review glaucomatous animal models, which are suitable to study stem cell-based therapies for TM regeneration.

Delivery strategies for porphyrinoid-based photosensitizers for use in therapeutic applications are based on a myriad of factors, which include porphyrinoid structure, solubility and cellular targets. These drug-delivery methods include encapsulation, hydrogels, protein carriers, nanoparticles and polymeric micelles among others. This article reviews the strategies for delivering porphyrinoids published to date and will focus on porphyrins, corroles, chlorins, bacteriochlorins, porphyrazines and phthalocyanines. Highlighted are the most recent and different strategies used for each of the corresponding porphyrinoid-based macrocycles.

Introduction: We estimated the effects of cardiorespiratory fitness (CRF) and body mass index (BMI) at baseline on mortality and cardiovascular disease events in people with type 2 diabetes who participated in the Look AHEAD randomized clinical trial. Methods: Look AHEAD compared effects of an intensive lifestyle intervention with diabetes support and education on cardiovascular disease events in 5145 adults age 45-76 yr with overweight/obesity and type 2 diabetes. In 4773 participants, we performed a secondary analysis of the association of baseline CRF during maximal treadmill test (expressed as metabolic equivalents (METs)) on mortality and cardiovascular disease events during a mean follow-up of 9.2 yr. Results: The mean (SD) CRF was 7.2 (2.0) METs. Adjusted for age, sex, race/ethnicity, BMI, intervention group, and β-blocker use, all-cause mortality rate was 30% lower per SD greater METs (hazard ratio (HR) = 0.70 (95% confidence interval, 0.60 to 0.81); rate difference (RD), −2.71 deaths/1000 person-years (95% confidence interval, −3.79 to −1.63)). Similarly, an SD greater METs predicted lower cardiovascular disease mortality (HR, 0.45; RD, −1.65 cases/1000 person-years) and a composite cardiovascular outcome (HR, 0.72; RD, −6.38). Effects of METs were homogeneous on the HR scale for most baseline variables and outcomes but heterogeneous for many on the RD scale, with greater RD in subgroups at greater risk of the outcomes. For example, allcause mortality was lower by 7.6 deaths/1000 person-years per SD greater METs in those with a history of cardiovascular disease at baseline but lower by only 1.6 in those without such history. BMI adjusted for CRF had little or no effect on these outcomes. Conclusions: Greater CRF is associated with reduced risks of mortality and cardiovascular disease events.

A series of glycosylated photosensitizers (porphyrin, chlorin, and isobacteriochlorin) in the presence of plasma proteins: bovine serum albumin (BSA) and human serum albumin (HSA), were investigated in a buffer at pH 7.4, using ultraviolet-visible (UV-vis) absorption and fluorescence spectroscopies. Due to the excitation of the tryptophan residue of BSA and HSA, its fluorescence emission was monitored around 340 nm. During each titration experiment and with each addition of the corresponding glycosylated photosensitizer, there was a concentration-dependent quenching of the intrinsic fluorescence of BSA and HSA. Using Stern–Volmer and double logarithmic plots we determined that fluorescence quenching was static for all molecules. We calculated the average binding constant for BSA and HSA for each porphyrin-type compound. To support our experimental studies, computational molecular docking and molecular dynamics simulations were used to identify the binding sites and binding poses of the each of the glycosylated photosensitizers onto BSA and HSA. The three compounds are binding to the Hemin site located in the subdomain IB of BSA forming strong interactions with Trp134, while they are binding to the subdomain IIA of HSA close to the Sudlow’s site I, and interacting with Trp214.